Precise tumor targeting with logic CAR circuits09/17/2021 - 08/31/2026 (Multi-PI)
PI:
Wilson Wong, PhDNIH/National Cancer Institute5U01CA265713-02
Precise targeting of T1D specific T cells using CAR and peptide-MHC chimeric antigen ligands05/15/2022 - 04/30/2026 (PI)
NIH/National Diabetes & Digestive & Kidney Diseases5R01DK132576-02
Targeting Fibroblast Discoidin Domain Receptor 2 for Immunotherapy to Pulmonary Fibrosis12/01/2021 - 11/30/2025 (Subcontract PI)
Regents of the University of Michigan NIH NHLBI5R01HL156998-02
Multiplexed Optogenetic Control of Mammalian Genome and Transcriptome using Recombinases and Cas1307/01/2023 - 06/30/2025 (Key Person / Mentor)
NIH/National Institute of General Medical Sciences1F31GM149163-01A1
Multiplexed and Logical Control of The Mammalian Transcriptome Using Cas1309/20/2021 - 06/30/2025 (PI)
NIH/National Institute of Biomedical Imaging & Bioengineering5R01EB031904-03
Engineering Branching Networks Through Synthetic Turing Morphogen Circuits12/10/2021 - 12/09/2024 (Multi-PI)
PI:
Wilson Wong, PhDAllen Institute d/b/a The Paul G. Allen Frontiers Group
Design and in vivo comparison of alternative strategies for artificial Zinc Finger (aZnF) based regulatable gene therapies03/04/2022 - 09/03/2024 (Multi-PI)
PI:
Wilson Wong, PhDNovartis Institutes for BioMedical Research
Synthetic morphogenesis to recapitulate multicellular airway branching patterns04/01/2023 - 03/31/2024 (Key Person / Mentor)
PI:
Ian Kinstlinger, PhDNIH/National Heart, Lung, and Blood Institute1F32HL160194-01A1
Advanced recombinase-based gene expression technology in mammalian cells06/01/2019 - 02/29/2024 (PI)
NIH/National Institute of General Medical Sciences5R01GM129011-04
Synthetic toolkit for precision gene expression control and signal processing in mammalian cells05/01/2020 - 01/31/2024 (Multi-PI)
PI:
Wilson Wong, PhDNIH/National Institute of Biomedical Imaging & Bioengineering5R01EB029483-04
Showing 10 of 24 results.
Show All Results
High-throughput chemical imaging for optimizing biofuel synthesis using synthetic biology09/15/2018 - 09/14/2023 (Multi-PI)
PI:
Wilson Wong, PhDDepartment of EnergyDE-SC0019387
Engineering CAR T Cells to Establish Stable Mixed Chimerism in Allogeneic Transplantation09/01/2022 - 08/31/2023 (Key Person / Mentor)
NIH/National Heart, Lung, and Blood Institute1F31HL162477-01A1
Signals that establish and maintain HIV latency05/08/2018 - 04/30/2023 (Subcontract PI)
Boston Medical Center Corporation NIH NIAID5R01AI138960-03
Evaluating NOT-gated CARs in NK cells09/01/2019 - 08/31/2022 (PI)
Senti Biosciences
Advanced Recombinase Technology for Tissue Engineering Applications09/01/2019 - 04/30/2022 (Key Person / Mentor)
NIH/National Heart, Lung, and Blood Institute5F31HL149334-03
CAREER: Deciphering and recording temporal events in mammalian cells using synthetic biology03/15/2016 - 02/28/2022 (PI)
National Science FoundationCBET-1553356
Engineering a smart CAR platform for human regulatory T cells09/30/2019 - 09/29/2021 (PI)
NIH/National Institute of Biomedical Imaging & Bioengineering1R56EB027729-01A1
Engineering genetic logic circuits in mammalian cells to accelerate high-throughput drug screening12/07/2017 - 10/30/2020 (PI)
Novartis Institutes for BioMedical Research
Bilateral BBSRC/NSF/BIO:Rewritable biocomputers in mammalian cells08/15/2016 - 07/31/2019 (PI)
National Science FoundationMCB-1614642
Development of rejuvenation method of hematopoietic system using CAR T cells02/01/2018 - 03/31/2019 (PI)
Kanae Foundation for the Promotion of Medical Science
EAGER: Biomanufacturing: Engineering genetic classifiers to increase the homogeneity of CAR T cells with central memory phenotype01/01/2017 - 12/31/2018 (PI)
National Science FoundationCBET-1645169
Synthetically Reengineered T Cells as the Next Generation of Smart Cancer Therapy09/30/2013 - 06/30/2018 (PI)
NIH/National Cancer Institute1DP2CA186574-01
Development of Inducible Gene Expression System for Cellular Immunotherapy02/26/2016 - 11/04/2016 (PI)
Lentigen Technology Inc.
Identification of Signals Required for the Establishment of HIV infection and Latency09/02/2015 - 08/31/2016 (Subcontract PI)
Boston Medical Center Corporation NIH NIAID1R56AI118682-01
Disabling HIV provirus by promoting Chromatinization07/01/2017 - 06/30/2019 (Activity-level PI)
PI:
Andrew J. Henderson, PhDAmerican Foundation for AIDS Research